Consent given pursuant to Sections 14 and 14A for the importation and supply of the therapeutic goods specified by Pfizer Consumer Healthcare

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods in Australia, including medicines, medical devices, and other health-related products. The Act was introduced to address the need for a comprehensive and cohesive regulatory system to ensure the safety, quality, and efficacy of therapeutic goods available to the public. The enacting body for this legislation was the Parliament of the Commonwealth of Australia, with the aim of protecting public health by controlling the therapeutic goods market. In the specific case of the Therapeutic Goods Act 1989, the policy objective is to ensure that therapeutic goods available in Australia are of acceptable quality, performance, and safety. On 18 March 2015, the delegate of the Secretary of the Department of Health granted consent to the importation and supply of a particular batch of Centrum Specialist Vision Plus, which did not fully conform with the standards set out in the Therapeutic Goods Order No. 78. The active ingredients, Lutein and Zeaxanthin, exceeded the permitted levels on the product label. The consent, issued under sections 14 and 14A of the Act, was subject to specific conditions to ensure the content of these active ingredients fell within acceptable limits. This case demonstrates the Act's role in allowing for flexibility in certain circumstances, while still maintaining stringent quality controls for therapeutic goods in Australia.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration, applies to a wide range of therapeutic goods, including medicines, medical devices, blood, tissues, and therapeutic goods that emit radiation. The Act encompasses persons and entities involved in the importation, manufacture, supply, and advertising of these goods within Australia. This legislation has a national reach, governing activities across the Commonwealth, states, and territories. Section 14 and 14A of the Act allow for specific consents to be granted in exceptional circumstances, such as the case of batch J82273 of Centrum Specialist Vision Plus, which did not conform to the standards set by TGO 78. The Act's scope extends to ensuring the quality, safety, and efficacy of therapeutic goods, and it provides for the imposition of conditions to mitigate any potential risks associated with non-conformance. Any subordinate instruments or regulations further detail the application and enforcement of the Act, ensuring compliance and protecting public health.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") governs the importation, supply, and other activities concerning therapeutic goods in Australia. Section 14 of the Act allows the Secretary of the Department of Health to give consent for the supply of goods that do not conform to certain standards, provided certain conditions are met. In the case of batch J82273 of Centrum Specialist Vision Plus, the Secretary's delegate has granted consent for the importation and supply of this batch, which does not conform to the requirements of TGO 78 regarding the content of the active ingredients Lutein and Zeaxanthin (section 14(b)). This consent is subject to specific conditions outlined in section 14A of the Act, which include limitations on the content of these active ingredients (section 14A(1)). Under the Act, the delegate of the Secretary has imposed conditions on the consent granted for the batch J82273. These conditions ensure that the content of Lutein and Zeaxanthin in the batch must be between 90.0% and 160.0% of the stated content on the label. This means that while the batch does not meet the full standard set out in TGO 78, it is still permissible for supply if the content of the active ingredients falls within the specified range. These conditions are designed to balance the need for regulatory compliance with the availability of therapeutic goods that might otherwise be unavailable if strict adherence to the standards were mandatory. Failure to comply with the conditions of consent, or with any other obligations imposed by the Act, may lead to various consequences. While the specific provisions of the Act do not detail offences, penalties, or consequences for non-compliance with the consent conditions in this instance, breaches of the Act generally can result in both civil and criminal penalties. Civil penalties can include fines, and in some cases, criminal penalties such as imprisonment may apply. The maximum penalties for breaches of the Therapeutic Goods Act can vary depending on the nature and seriousness of the offence, but they can include substantial fines for corporations and imprisonment for individuals, reflecting the seriousness with which the Act is enforced to protect public health and safety. The Therapeutic Goods Act 1989 and its associated regulations provide a comprehensive framework for the regulation of therapeutic goods in Australia. By allowing for consent to be granted under specific conditions, the Act ensures that essential therapeutic goods can still be made available to the public while maintaining a high standard of quality and safety. The conditions imposed on the consent for batch J82273 of Centrum Specialist Vision Plus are a practical application of this principle, balancing regulatory requirements with public health needs.